ストックスクリーナーアプリを入手
3.1701
0.00%
0.0001
前日終値:
$3.17
開ける：
$3.18
24時間の取引高:
20,072
Relative Volume:
0.02
時価総額：
$23.17M
収益：
-
当期純損益:
$-16.60M
株価収益率:
-3.5619
EPS:
-0.89
ネットキャッシュフロー:
$-23.48M
1週間 パフォーマンス:
-3.06%
1か月 パフォーマンス:
-27.62%
6か月 パフォーマンス:
-64.48%
1年 パフォーマンス:
-89.98%
1日の値動き範囲:
$3.11
$3.22
1週間の範囲:
$3.04
$3.34
52週間の値動き範囲:
$3.04
$30.78
Briacell Therapeutics Corp Stock (BCTX) Company Profile
名前
Briacell Therapeutics Corp
セクター
電話
(604) 921-1810
住所
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
BCTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.1701 | 23.17M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.54 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.00 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.84 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.04 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-14 | 開始されました | H.C. Wainwright | Buy |
Briacell Therapeutics Corp (BCTX) 最新ニュース
(BCT) Comprehensive Trading Strategy Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Risk-Controlled Trading Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Trading Advice (BCT:CA) - news.stocktradersdaily.com
(BCT) Investment Performance Report (BCT:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - PR Newswire
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Br - GuruFocus
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
How To Trade (BCT) (BCT:CA) - news.stocktradersdaily.com
BriaCell’s Phase 3 Data Shows Promise for Metastatic Breast Cancer Treatment - TipRanks
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Breast Cancer Study | BCTX Stock News - GuruFocus
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Posit - GuruFocus
Buy This Dividend-Paying Tech Stock to Play the Low-Cost China AI Story - The Globe and Mail
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: - GlobeNewswire
Game-Changing Cancer Biomarkers: BriaCell Phase 3 Data Shows How to Predict Treatment Success - Stock Titan
Occidental’s Hidden Gem: How OxyChem Could Boost Profits - The Globe and Mail
BriaCell (BCTX) Reveals Promising Phase 2 and Preclinical Data a - GuruFocus
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Therapeutics closes $13.8M public offering - MSN
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering - The Manila Times
Briacell Therapeutics Announces Closing Of $13.8 Million Public Offering - marketscreener.com
BriaCell Secures $13.8M Funding Boost: New Capital to Accelerate Cancer Immunotherapy Development - Stock Titan
Vitalhub Corp. - Baystreet.ca
BriaCell Presents Benchmark Beating Survival and Clinical Benefi - GuruFocus
BriaCell’s Breakthrough in Cancer Immunotherapy at AACR 2025 - TipRanks
BriaCell Presents Benchmark Beating Survival and Clinical - GlobeNewswire
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development - The Manila Times
BriaCell's Breast Cancer Immunotherapy Shows Breakthrough 17.3-Month Survival in Latest Trial Data - Stock Titan
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - MSN
Briacell Therapeutics Corp. - MENAFN.com
Littelfuse Earnings: What To Look For From LFUS - The Globe and Mail
(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX) Prices Public Offering of Units to Raise $13.8 M - GuruFocus
Increased Share Offering for XYZ Corp (XYZ) Priced Below Market - GuruFocus
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offerin - GuruFocus
BriaCell Therapeutics to Raise $13.8 Million in Public Offering; Shares Fall - marketscreener.com
BriaCell's Stock Dips Following Public Offering Announcement - Finimize
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offering - GuruFocus
BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering - marketscreener.com
BriaCell Therapeutics announces pricing of $13.8 million public offering - MSN
(BCT) Trading Report (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail’s Busy Cheering Clinical Milestone - Investing.com India
BriaCell Therapeutics Announces $13.8 Million Public Offering - TipRanks
BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option - Stock Titan
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering - The Manila Times
Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million - marketscreener.com
BriaCell reports complete lung metastasis resolution in breast cancer study By Investing.com - Investing.com South Africa
BriaCell's Bria-OTS shows sustained success against breast cancer | 2025-04-24 | Investing News - Stockhouse
BriaCell confirms 100% resolution of lung metastasis with Bria-OTS - TipRanks
Briacell Therapeutics Corp (BCTX) 財務データ
収益
当期純利益
現金流量
EPS
0.44%
0.28%
大文字化:
|
ボリューム (24 時間):